Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.35 USD
-0.02 (-1.46%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.35 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum A VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 30% (74 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.58 | 9.99 |
Current Quarter Estimate | -0.05 | -1.17 | 61.00 |
Year Ago Quarter Estimate | -0.08 | -0.06 | 54.84 |
Next Quarter Estimate | -0.03 | -1.92 | 63.00 |
Next Year Estimate | -0.17 | 12.59 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 32.14 | 20.00 | 15.67 |
Next Year | 10.53 | 15.30 | 11.34 |
Last 5 Years | NA | 7.80 | 8.10 |
Next 5 Years | NA | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -1.44 |
Price/Book (MRQ) | NA | 1.59 |
Price/Cash Flow (MRFY) | NA | 9.47 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -23.18% | -61.35% |
Return on Equity (TTM) | NA | -58.93% |
Debt to Equity (MRQ) | -1.31 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.